NVSTHealthcare · Medical Instruments & SuppliesThe 16 Wall Street analysts covering Envista Holdings Corp. hold a median 12-month price target of $31 — +10.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 17 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Envista Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (97): Analysts have, on balance, been raising their forecasts.
Quality (70): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (25): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NVST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +10.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | Piper Sandler | Reiterates | Neutral | $26 → $28 |
| 29 July 2026 | Piper Sandler | Maintains | Neutral | $25 → $26 |
| 29 July 2026 | Piper Sandler | Maintains | Neutral | — |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | — |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | $27 |
| 11 June 2026 | Barclays | Maintains | Overweight | — |
| 7 May 2026 | Baird | Maintains | Outperform | — |
| 7 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 7 May 2026 | JP Morgan | Maintains | Neutral | — |
| 24 Apr 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 15 Apr 2026 | Citigroup | Initiates | Neutral | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 11 Feb 2026 | Barclays | Maintains | Overweight | — |
| 10 Feb 2026 | Mizuho | Maintains | Neutral | — |
| 6 Feb 2026 | JP Morgan | Maintains | Neutral | — |
| 6 Feb 2026 | Piper Sandler | Reiterates | Neutral | — |
| 6 Feb 2026 | Stifel | Maintains | Buy | — |
| 6 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 4 Feb 2026 | Stifel | Maintains | Buy | — |
| 3 Feb 2026 | UBS | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NVST appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 16% of US stocks
Cheaper than 59% of US stocks
Cheaper than 57% of US stocks
Cheaper than 33% of US stocks
Higher than 45% of US stocks
Higher than 85% of US stocks
Higher than 69% of US stocks
Higher than 67% of US stocks
Higher than 56% of US stocks
Higher than 50% of US stocks
Higher than 67% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Envista Holdings Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights Envista (NVST) as a strong momentum stock, noting that stocks like this can be identified using the Zacks Style Scores feature of the Zacks Premium research service.
Why it matters — A NVST watcher would care because the item signals that the stock is being recognized by a major research service for strong momentum characteristics.
Envista Holdings raised its 2026 guidance, citing stronger sales, expanding margins, and higher earnings. The report also flags potential headwinds including China pricing pressures, tariffs, and a tougher fourth quarter.
Why it matters — NVST watchers would follow this because the improved outlook signals earnings strength even as China pricing, tariffs, and Q4 conditions could challenge how well the company sustains the boost.
Zacks reported that Envista's earnings have rebounded and the company raised its 2026 guidance, though its valuation remains above the median, leaving less room for execution missteps.
Why it matters — NVST watchers would care because the earnings recovery and guidance raise are positive signals, but the above-median valuation means the stock may be more vulnerable to any operational setbacks.
A Zacks Investment Research article highlights four value stocks selected for low PEG ratios, strong earnings growth prospects, and favorable value scores, positioning them as potential options beyond traditional P/E-based screening.
Why it matters — The piece draws attention to value-oriented names like those covered on the NVST page, giving watchers context on how such stocks are being screened for valuation and growth.
Envista Holdings Corp. (NVST) was included in Zacks Investment Research's list of top momentum stocks to buy, receiving a Zacks Rank #1 (Strong Buy) designation as of August 10, 2026.
Why it matters — Inclusion in the Zacks Rank #1 (Strong Buy) momentum stocks list signals that NVST is viewed favorably by the research firm based on momentum factors.
The 16 Wall Street analysts covering Envista Holdings Corp. have a median 12-month price target of $31, with estimates ranging from $23 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Envista Holdings Corp., 7 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Envista Holdings Corp. 98 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 17 Aug 2026, Envista Holdings Corp. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +10.3% from the last close, and Ticker Nerd's factor model ranks Envista Holdings Corp. 98 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Envista Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $35 over the next 12 months.
Envista Holdings Corp. returned +34.0% over the 12 months to 17 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Envista Holdings Corporation is a global leader in developing, manufacturing, and marketing a wide range of dental equipment and technology. Operating primarily within the dental industry, the company serves dental professionals with innovative products and solutions.
The most recent item we track (Zacks Investment Research, 17 Aug 2026): "Here's Why Envista (NVST) is a Strong Momentum Stock". Zacks Investment Research highlights Envista (NVST) as a strong momentum stock, noting that stocks like this can be identified using the Zacks Style Scores feature of the Zacks Premium research service.
Envista Holdings Corporation is a global leader in developing, manufacturing, and marketing a wide range of dental equipment and technology. Operating primarily within the dental industry, the company serves dental professionals with innovative products and solutions. Envista is particularly well-known for its comprehensive offerings in dental consumables, orthodontic appliances, and imaging equipment, which are essential tools for modern dental practices and laboratories. The corporation plays a crucial role in enhancing dental care quality by providing cutting-edge technology and promoting digital dentistry. Envista supports various sectors within dentistry, including preventive care, implantology, and orthodontics, making it integral to dental health professionals worldwide. With a commitment to research and development, Envista continuously brings advancements to the dental market, fostering improved patient outcomes and efficiency in dental services. As a significant industry player, Envista Holdings Corporation contributes to setting benchmarks for innovation and technology integration in healthcare, positioning itself as a key entity in the global dental market landscape.
CEO Mr. Paul A. Keel · 12,000 employees · United States · https://envistaco.com